相关实验视频
Updated: Jun 8, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
评估甲胺不耐受:一个回顾性图表审查
Pilar Z Murphy1, Alanna Bramwell-Shittu2, Kaci Boehmer1
1University of Arkansas for Medical Sciences College of Pharmacy and College of Medicine.
Innovations in pharmacy
|November 1, 2024
概括
低体重指数 (BMI) 和慢性病 (CKD) 的2型糖尿病患者不太可能被处方甲胺. 这些非甲胺使用者往往具有糖尿病前血红蛋白A1c (A1c) 水平.
科学领域:
- 内分泌学 在内分泌学.
- 主要护理医学 医疗保健
- 临床药房 临床药房
背景情况:
- 甲胺是2型糖尿病的第一线治疗方法.
- 了解与不使用甲福明相关的患者特征对于优化糖尿病管理至关重要.
- 居民主导的初级保健诊所为各种患者群体提供服务,使其成为此类调查的理想场所.
研究的目的:
- 为了比较2型糖尿病患者在接受甲福明治疗的特征与未接受甲福明治疗的患者.
- 为了确定在初级保健机构中不使用甲胺的潜在原因.
- 探索不耐受或不使用甲胺的患者之间的相似之处.
主要方法:
- 在家庭医学诊所对2型糖尿病成年患者的回顾性图表审查.
- 对比一组非甲胺使用者 (n=216) 与甲胺使用者 (n=869) 的队列.
- 数据收集包括体重指数 (BMI),血红蛋白A1c (A1c),功能 (CKD) 和记录的甲胺不耐受.
主要成果:
- 与使用者相比,不使用甲胺的人的平均BMI显著降低 (30.87比35.43),慢性病率更高 (25.93%比14.73%).
- 体重指数与甲福明使用正相关,而CKD与甲福明使用负相关.
- 在非使用甲福明的患者中,有很大比例的人患有糖尿病前A1c水平 (5-6.4%),其中一些人接受胰岛素治疗.
结论:
- 较低的BMI和CKD的存在与2型糖尿病患者的甲福明处方可能性降低有关.
- 没有接受甲福明治疗的患者可能会出现低于最佳的血糖控制,许多患者会进入糖尿病前A1c范围.
- 进一步的研究是有必要的,以了解甲福林启动的障碍,并探索非符合条件的患者的替代疗法.
更多相关视频
相关概念视频
Diabetes: Symptoms, Diagnosis, and Complications
508
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
508
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
160
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
160
Dipeptidyl Peptidase 4 Inhibitors
172
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172
Assessment of the Gastrointestinal System I: Subjective Data
152
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
152

